N-acetylcysteine and atorvastatin alleviates lung injury due to ischemia-reperfusion injury in rats : Journal of the Chinese Medical Association

Secondary Logo

Journal Logo

Original Articles

N-acetylcysteine and atorvastatin alleviates lung injury due to ischemia-reperfusion injury in rats

Guo, Da-Weia,b; Wang, Chien-Yingc; Shih, Hsin-China,c,*

Author Information
Journal of the Chinese Medical Association 82(12):p 909-914, December 2019. | DOI: 10.1097/JCMA.0000000000000193
  • Open



Ischemia-reperfusion (IR) injury is the most common and serious sequela of resuscitation from major surgery, severe injury, and hemorrhagic shock.1 Restoration of mesenteric blood flow, frequently forgone early in shock, may contribute to IR injury pathogenesis.2 Reactive oxygen species (ROS) formation, lipid peroxidation, and inflammatory responses mainly mediated IR injury, resulting in systemic inflammatory response syndrome (SIRS). SIRS can induce secondary injury to distant organs, causing remote organ failure, multiple organ dysfunction, or even death.3,4 These injuries manifest as inflammatory cytokine release, oxygen free-radical formation, and neutrophil infiltration in injured tissue. Acute lung injury is the most severe remote organ injury and one of the primary cause of death after IR injury.5,6 ROS formation is the primary pathogenesis of lung injuries due to mesenteric IR injury. ROS, generated in damaged tissues and cells, trigger the activation of various signaling pathways, promote the inflammatory reaction, and damage the intestinal mucosal barrier function in the process of intestinal IR injury. IR allows ROS to escape gut microvasculature into systemic circulation and generate a cascade of various biological events, including acute lung injury.3,7

Various anti-inflammatory drugs including antioxidant and antiapoptotic drugs are used for preventing tissue injury.8,9 N-acetylcysteine (NAC) and atorvastatin (ATOR) have pleiotropic effects and are strong antioxidants, which reduce oxidative stress and prevent IR injury. NAC, a sulfhydryl group transmitter commonly used in clinical practice, is a strong antioxidant, which directly scavenges ROS through its thiol groups, increasing intracellular glutathione levels.10 A study noted substantial alleviation of IR injury and reduction of remote organ dysfunction in NAC-treated animals.11 Therefore, NAC can exert therapeutic effects in other diseases, acting on oxidative stress, inflammation, and apoptosis.12 ATOR is an antidyslipidemic for lowering cholesterol and primary and secondary prevention of cardiovascular diseases.13 The pleiotropic of ATOR are characterized by their potent anti-inflammatory properties, immunomodulation, antithrombotic action, endothelial function improvement, and antioxidative properties.14 The NAC and ATOR are supposed to act as anti-inflammatory drugs through different pathways. In present study, we evaluated the therapeutic efficacy of pretreatment with NAC alone, ATOR alone, and NAC combined with ATOR in preventing lungs injury following IR of the superior mesenteric artery (SMA) in rats.


The study was approved by the Institutional Animal Care and Use Committee (IACUC) of National Yang-Ming University (IACUC number: 1021294). All animals were managed according to the Guide for the Care and Use of Laboratory Animals.

2.1. Experimental groups

In total, 30 male Sprague Dawley rats, weighing 250-300 g and aged 7-8 weeks were obtained from BioLasco Taiwan Co. Ltd (Taipei City, Taiwan). All rats were fed standard rat chow and filtered water and kept under constant standard conditions: room temperature (23°C ± 2°C), 55% ± 5% humidity, and 12-h light-dark cycle. The following drugs were administered as follows: NAC (Nang Kuang Pharmaceutical Co. Ltd., Tainan, Taiwan), ATOR (Pfizer Inc., New York, NY, USA), NAC + ATOR, or placebo (0.9% NaCl) for 3 days before surgery. The final dose of drugs was administered 12 hours before surgical manipulation. Animals were randomly allocated to five experimental groups (n = 6 for each group) as follows: (1) sham group (no pretreatment and sham for mesenteric IR); (2) IR group (placebo through oral gavage and intraperitoneal injection, followed by mesenteric IR); (3) ATOR group (ATOR, 40 mg/kg body weight/d, through oral gavage, followed by mesenteric IR); (4) NAC group (NAC, 300 mg/kg body weight/d, through intraperitoneal injection, followed by mesenteric IR); and (5) ATOR + NAC group (A + N; both drugs followed by mesenteric IR).

2.2. Mesenteric IR

Mesenteric IR was performed according to our previous study.15 Animals were exposed to 3% isoflurane gas for inducing anesthesia. The animals were placed in the supine position and the anterior abdominal wall was cleaned and shaved followed by subcutaneous injection of 1-2 mL of 2% lidocaine hydrochloride for analgesia. Throughout the perioperative and postoperative periods, body temperature was maintained at 37°C-38°C by using a controlled heating blanket. A 2 cm midline laparotomy incision was made. The SMA was gently isolated and a traumatic microvascular clamp was placed on the SMA for 60 minutes. Mesenteric ischemia was confirmed when mesenteric pulsation was lost and the intestinal segment became pale. The bowel was returned to the abdominal cavity, and the incision was closed using interrupted 4-0 nylon sutures. After 60 minutes of ischemia, the abdomen was reopened, and the vascular clamp was removed. Mesenteric reperfusion was confirmed by the return of pulsation and color, and the bowel was then returned to the abdominal cavity, which was closed again. After 60 minutes of reperfusion, the animals were exsanguinated through the inferior vena cava and sacrificed. The subsequent sampling and analysis were performed using numbers tags rather than groups to ensure blindness in the experiments.

2.3. Blood analysis

Blood samples were collected in an Eppendorf tubes (Scientific Specialties, Lodi, CA, USA). The serum was separated by centrifuging whole blood (3000 g for 10 min at 4°C). Blood gas analysis was performed on VetStat Electrolyte and Blood Gas Analyzer (IDEXX Laboratories, Inc., Westbrook, ME, USA). Chemical analysis of serum was performed on VetTest Chemistry Analyzer (IDEXX Laboratories, Inc.). Whole-blood analysis was performed on Sysmex XT-1800iv (Sysmex Europe GmbH, Co., Norderstedt, Germany).

2.4. Histopathology

Lung samples from the most superior region of the right middle lobe (nondependent site) and the most inferior region of the superior-posterior segment of the right lower lobe (dependent site) were obtained with a constant positive end-expiratory pressure (5 cm H2O). These samples were immersed in buffered 4% formaldehyde, embedded in paraffin, and cut into sections before staining with hematoxylin and eosin. The lung histology slides were examined and scored by a blinded pathologist. The lung tissues of the rats were harvested by one of the authors. Lung histology slides were prepared by a specialist and marked using sequential numbers. The pathologist who examined and scored the observations was blinded to this study.

Injury was scored according to the presence of abnormal observations, namely alveolar hemorrhage, interstitial inflammatory cells, edema, and necrosis. On the histology slides, injury severity was graded using a 5-point scale: if no, <1/4, 1/4-1/2, 1/2-3/4, or ≥3/4 part of the area of microscopic field included the abnormal observations, the slide was scored as 0, 1, 2, 3, and 4, respectively. For each slide, five or more fields were examined to minimize regional variations.

2.5. Wet-to-dry lung weight ratio

An index of pulmonary edema was determined using the wet-to-dry lung weight (W/D) ratio. The left lower lung was excised and weighed immediately (wet weight). The lung tissue was then dried in an oven for 5 days at 60°C and reweighed (dry weight). The W/D was calculated by dividing the wet weight by the dry weight, as described previously.16

2.6. Cytokine levels

The left upper lung was excised and rinsed with phosphate-buffered saline to remove excess blood. A 0.5-g piece of lung tissue was manually homogenized in 1 mL of tissue protein extraction reagent (Thermo Fisher Scientific Inc., Waltham, MA, USA) and total protein concentrations were determined using Pierce BCA protein assay kit (Thermo Fisher Scientific Inc.). The concentration of interleukin (IL)-1β, IL-6, and tumor necrosis factor (TNF)-α were determined using an enzyme-linked immunosorbent assay (ELISA) kit (DuoSet rat; R&D Systems, Minneapolis, MN, USA) according to manufacturer's instructions. The optical density was read at 450 nm, with a reference wavelength of 540 nm, on the TECAN Infini 200 (Tecan Group Ltd., Männedorf, Switzerland) ELISA reader. All assays used recommended buffers, diluents, and substrates. The linear graph for cytokine levels was obtained using a series of eight 2-fold dilutions of rat IL-1β (4000-62.5 pg/mL), IL-6 (8000-125 pg/mL), and TNF-α (4000-62.5 pg/mL) standard; to quantify tissue cytokine levels, readings were compared with a standard concentration curve created using MS Excel (Microsoft Corporation, Redmond, WA, USA).

2.7. Statistical analysis

Statistical analysis was performed using SigmaPlot 13 for Windows (Systat Software, Inc., Chicago, IL, USA). All data are presented as medians with a range. Differences between groups were assessed through Kruskal-Wallis one-way analysis of variance by ranks and Dunn's post hoc test. Differences within groups were assessed using paired t test to compare lung injury score data between nondependent and dependent sites. A p value of <0.05 was considered statistically significant.


3.1. Blood analysis

3.1.1. Cell counts

Total leukocyte counts did not differ among the groups. Percentage of neutrophils/lymphocytes (N/L) was significantly lower in the pretreatment groups than in the IR group; there was no significant difference among the pretreatment groups (Table).

Blood analysis for cell counts and biochemistry

3.1.2. Biochemistry

Serum lactate, blood urea nitrogen, creatinine, aspartate aminotransferase, alanine aminotransferase (ALT), and alkaline phosphatase (ALKP) were assayed. Compared with those in the IR group, lactate and ALT levels were significantly lower in all pretreatment groups, and creatinine and ALKP levels were significantly lower only in the A + N group (Table).

3.1.3. Blood gas

Vein gas exchange levels were presented. Compared with those in the sham group, pH was lower and bicarbonate (HCO3-)levels, and base excess (BE) were lower and partial pressure of carbon dioxide (PvCO2) was higher in the IR group. Compared with those in the IR group, pH and BE were significantly higher and PvCO2 significantly lower in the ATOR and A + N groups (Fig. 1A, B, D), significantly higher HCO3 was noted only in the A + N group (Fig. 1C).

Fig. 1:
Vein gas exchange levels at the end of the experimental period. Data are presented as medians with total range. Sham (n = 6), no injury; IR (n = 6), no pretreatment; ATOR (n = 6), atorvastatin administered through gavage; NAC (n = 6), N-acetylcysteine administered intraperitoneally; and A + N (n = 6), both drugs administered. *p < 0.05 vs IR group. Vein gas pH (A); vein gas BE (B); vein gas PvCO2 (C); vein gas HCO3 levels (D). A + N, atorvastatin + N-acetylcysteine; ATOR, atorvastatin; BE, base excess; HCO3-, bicarbonate; IR, ischemia-reperfusion; NAC, N-acetylcysteine; PvCO2, partial pressure of carbon dioxide; SHAM, sham treatment.

3.2. Lung injury evaluation

3.2.1. Histopathology

The histopathological findings of lung injury in the experimental groups are presented in Figure 2. Increased leukocyte infiltration, edema, and hemorrhage were noted after IR. The lung injury score analysis showed decreased injury in all pretreatment groups compared with the IR group; however, significant alleviation was noted only in the A + N group (Fig. 2).

Fig. 2:
Lung injury evaluation. Representative pulmonary histological photographs of the five experimental groups. Increased leukocyte infiltration, edema, and hemorrhage were noted after IR (arrows). Pretreatment decreased the lung inflammatory infiltration. The sums of lung injury scores are presented as medians with total range. *p < 0.05 vs IR group. A + N, atorvastatin + N-acetylcysteine; ATOR, atorvastatin; IR, ischemia-reperfusion; NAC, N-acetylcysteine; SHAM, sham treatment.

3.2.2. Weight to dry ratio

A higher W/D was noted after IR. Although the pretreatment groups had lower W/D; however, a significant decrease was noted only in the A + N group (Fig. 3).

Fig. 3:
Lung wet-to-dry weight ratio. Edema formation (wet/dry weight) in lung tissue increased following mesenteric ischemia-reperfusion. Data are presented as medians with total range. *p < 0.05 vs IR group. A + N, atorvastatin + N-acetylcysteine; ATOR, atorvastatin; IR, ischemia-reperfusion; NAC, N-acetylcysteine; SHAM, sham treatment.

3.3. Cytokine levels

Proinflammatory cytokines, IL-1β, IL-6, and TNF-α, were analyzed as the biomarkers of acute inflammation in the lung tissue. Compared with the sham group, cytokine levels increased after IR. Compared with those in the IR group, TNF-α levels were significantly lower in all pretreatment groups, whereas IL-1β levels were significantly lower only in the A + N group (Fig. 4).

Fig. 4:
Lung tissue cytokine levels. Lung tissue levels of TNF-α (left), IL-1β (middle), and IL-6 (right) increased following mesenteric ischemia-reperfusion. Data are presented as medians with total range. *p < 0.05 vs IR group. A + N, atorvastatin + N-acetylcysteine; ATOR, atorvastatin; IL, interleukin; IR, ischemia-reperfusion; NAC, N-acetylcysteine; SHAM, sham treatment; TNF-α, tumor necrosis factor-α.


Here, in a rat model, NAC, ATOR, and NAC + ATOR protected against remote organ injury induced through mesenteric IR. However, compared with their individual use, the combined use of NAC and ATOR may result in superior biochemical outcomes, gas exchange activity, and lung function preservation. In the A + N group, the improvements in lung condition manifested as high HCO3 levels and low lung injury scores, W/Ds, and tissue IL-1 levels. Thus, the combination NAC + ATOR has anti-inflammatory or antioxidant properties and protect against mesenteric IR-induced acute lung damage.

IR injury pathophysiology plays a key role in oxidative stress elevation and mitochondrial dysfunction. The consequent harmful effects result in endoplasmic reticulum stress; the resulting ROS trigger the apoptotic cascade and stimulate an acute inflammatory response.16 Intestinal IR is expected during clinical stress, including shock and trauma.17 The lungs become vulnerable particularly after intestinal IR, and the first clinical symptoms precede multiple organ failures, leading to acute respiratory distress syndrome.3,18 Although the main mediators of IR-induced damage are inflammation and oxidative stress, the precise underlying mechanisms remain unclear. Similar to our previous study, here, we used an established and validated surgical technique for inducing intestinal IR under complete SMA occlusion.

NAC is a free-radical scavenger and glutathione precursor. We used a high NAC dose (300 mg/kg body weight). The NAC dose and administration pathway were similar to those used by Kalimeris et al19, who reported that higher doses (300 mg/kg body weight) of NAC before ischemia improved liver and lung functions more efficiently than did lower doses (150 mg/kg body weight). Cerqueira et al20 administered NAC through continuous infusion (430 mg/kg body weight/h) with effective protection. We noted the advantage of administering NAC after mesenteric IR to protect against remote organ injury, particularly in the lungs. The rats treated with NAC had significantly lower cytokine levels and less neutrophil sequestration in the lungs after IR injury than the untreated rats.

ATOR is a statin that has pleiotropic effects in addition to its cholesterol-lowering activity; the pleiotropic effects include endothelial function modulation, oxidative stress reduction, immunomodulation, and anti-inflammatory action.21 We administered a high daily dose of ATOR (40 mg/kg body weight) on the basis of a previous study.22 Relatively high statin concentrations may be necessary in animals, in whom the expression of 3-hydroxy-3-methylglutaryl coenzyme, a reductase, is rapidly upregulated in response to statin administration.23 A human study reported that a high ATOR dosage (80 mg/d) was associated with significantly reduced high-sensitivity C-reactive protein concentrations,24 but without serious adverse consequences. Here, ATOR was effective in limiting remote organ damage in intestinal IR models, thus corroborating its protective effects against IR injuries to the lungs, liver, and kidneys reported previously.25,26

We hypothesized that the combination of NAC and ATOR protects against remote organ injury, particularly to the lungs. Both drugs were selected because they are widely used in clinical practice. There are many types of statins, all of which have varied pharmacological properties, such as absorption, affinity, solubility, and excretion, and thus have significantly distinct lung-protective properties. However, in the current study, NAC + ATOR administration before IR injury prevented remote lung injury in rats, thus indicating that the combined use of both drugs limited lung injury more effectively than did their use individually.

To the best of our knowledge, only two studies thus far have investigated the protective effects of NAC and ATOR against lung IR injury:24,27 Cusumano et al22 administered NAC (140 mg/kg) and ATOR (40 mg/kg) to an IR model of rat kidney and found that both drugs modulated the oxidative activity; however, the number of tubular ischemic lesions was relatively low in their NAC + ATOR group. Alexandropoulos et al27 administered NAC (160 mg/kg) and ATOR (10 mg/kg) to an intestinal IR model and found that NAC and ATOR had relatively superior in kidney- and liver-protective effects, respectively, and that their combined use reduced systemic inflammatory cytokine levels. In our study, after NAC + ATOR use, the creatinine and ALKP levels significantly decreased, but no significant change was noted for other biochemistry markers. Differences in the blood sampling methods and timepoints used might reflect on the final results. Nevertheless, our study confirmed that the combined use of NAC and ATOR reduced the lung injury and modulated the blood gas levels and inflammation in the peripheral blood.

Our study has several limitations. First, we did not procure the blood volume before experiment for baseline measurement to negate the effect of blood loss on our final results; consequently, the lack of basal control values might have obscured the true effect of the drug treatments. Second, for sacrificing fewer rats, we did not add another group with sham treatment without sham IR, which might have clarified the medical sham effect on the final results. Third, we did not compare the molecular mechanisms underlying the protection from either individual or combined drug use; however, the additive effects of the drugs indicated that different pathways existed. Finally, the high drug doses and pretreatment requirement may restrict the use of these drugs in emergency clinical scenarios, such as acute injury.

In conclusion, pretreatment with NAC, ATOR, or their combination potentially protects against injuries to remote organs, such as the lungs. Moreover, the pretreatment with NAC + ATOR improved gas exchange, attenuated inflammatory cytokine secretion, and reduced lung injury severity in our mesenteric IR rat model. These data are of clinical value, particularly given the common use and relatively safety of NAC and ATOR.


The authors gratefully acknowledge Mei-Jy Jeng, MD, PhD, for her experiment technique help at Taipei Veterans General Hospital, Taipei, Taiwan.


1. Pierro A, Eaton S. Intestinal ischemia reperfusion injury and multisystem organ failure.Semin Pediatr Surg20041311–7
2. Hassoun HT, Kone BC, Mercer DW, Moody FG, Weisbrodt NW, Moore FA. Post-injury multiple organ failure: the role of the gut.Shock2001151–10
3. Carden DL, Granger DN. Pathophysiology of ischaemia-reperfusion injury.J Pathol2000190255–66
4. Schoenberg MH, Poch B, Younes M, Schwarz A, Baczako K, Lundberg C, et al. Involvement of neutrophils in postischaemic damage to the small intestine.Gut199132905–12
5. Sorkine P, Szold O, Halpern P, Gutman M, Greemland M, Rudick V, et al. Gut decontamination reduces bowel ischemia-induced lung injury in rats.Chest1997112491–5
6. Yellon DM, Hausenloy DJ. Myocardial reperfusion injury.N Engl J Med20073571121–35
7. Cuzzocrea S, Chatterjee PK, Mazzon E, Dugo L, De Sarro A, Van de Loo FA, et al. Role of induced nitric oxide in the initiation of the inflammatory response after postischemic injury.Shock200218169–76
8. Kosieradzki M, Rowiński W. Ischemia/reperfusion injury in kidney transplantation: mechanisms and prevention.Transplant Proc2008403279–88
9. Souza DG, Vieira AT, Soares AC, Pinho V, Nicoli JR, Vieira LQ, et al. The essential role of the intestinal microbiota in facilitating acute inflammatory responses.J Immunol20041734137–46
10. Takhtfooladi HA, Hesaraki S, Razmara F, Takhtfooladi MA, Hajizadeh H. Effects of N-acetylcysteine and pentoxifylline on remote lung injury in a rat model of hind-limb ischemia/reperfusion injury.J Bras Pneumol2016429–14
11. Weinbroum AA, Rudick V, Ben-Abraham R, Karchevski E. N-acetyl-L-cysteine for preventing lung reperfusion injury after liver ischemia-reperfusion: a possible dual protective mechanism in a dose-response study.Transplantation200069853–9
12. Circu ML, Aw TY. Glutathione and modulation of cell apoptosis.Biochim Biophys Acta201218231767–77
13. The Long-term Intervention with Pravastatin in Ischemic Disease (LIPID) Study GroupPrevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels.N Engl J Med19983391349–57
14. Mach F. Statins as immunomodulatory agents.Circulation200410921 Suppl 1II15–7
15. Shih HC, Huang MS, Lee CH. Estrogen augments the protection of hypertonic saline treatment from mesenteric ischemia-reperfusion injury.Shock201135302–7
16. Kalogeris T, Baines CP, Krenz M, Korthuis RJ. Cell biology of ischemia/reperfusion injury.Int Rev Cell Mol Biol2012298229–317
17. Schoenberg MH, Beger HG. Reperfusion injury after intestinal ischemia.Crit Care Med1993211376–86
18. He GZ, Dong LG, Chen XF, Zhou KG, Shu H. Lymph duct ligation during ischemia/reperfusion prevents pulmonary dysfunction in a rat model with ω-3 polyunsaturated fatty acid and glutamine.Nutrition201127604–14
19. Kalimeris K, Briassoulis P, Ntzouvani A, Nomikos T, Papaparaskeva K, Politi A, et al. N-acetylcysteine ameliorates liver injury in a rat model of intestinal ischemia reperfusion.J Surg Res2016206263–72
20. Cerqueira NF, Hussni CA, Yoshida WB, Sequeira JL, Padovani CR. Effects of pentoxifylline and n-acetylcysteine on injuries caused by ischemia and reperfusion of splanchnic organs in rats.Int Angiol200827512–21
21. Wassmann S, Laufs U, Müller K, Konkol C, Ahlbory K, Bäumer AT, et al. Cellular antioxidant effects of atorvastatin in vitro and in vivo.Arterioscler Thromb Vasc Biol200222300–5
22. Cusumano G, Romagnoli J, Liuzzo G, Ciavarella LP, Severino A, Copponi G, et al. N-acetylcysteine and high-dose atorvastatin reduce oxidative stress in an ischemia-reperfusion model in the rat kidney.Transplant Proc2015472757–62
23. Blanco-Colio LM, Tuñón J, Martín-Ventura JL, Egido J. Anti-inflammatory and immunomodulatory effects of statins.Kidney Int20036312–23
24. Bonnet J, McPherson R, Tedgui A, Simoneau D, Nozza A, Martineau P, et al.; CAP InvestigatorsComparative effects of 10-mg versus 80-mg atorvastatin on high-sensitivity C-reactive protein in patients with stable coronary artery disease: results of the CAP (comparative atorvastatin pleiotropic effects) study.Clin Ther2008302298–313
25. Siempos II, Maniatis NA, Kopterides P, Magkou C, Glynos C, Roussos C, et al. Pretreatment with atorvastatin attenuates lung injury caused by high-stretch mechanical ventilation in an isolated rabbit lung model.Crit Care Med2010381321–8
26. Wu K, Lei W, Tian J, Li H. Atorvastatin treatment attenuates renal injury in an experimental model of ischemia-reperfusion in rats.BMC Nephrol20141514
27. Alexandropoulos D, Bazigos GV, Doulamis IP, Tzani A, Konstantopoulos P, Tragotsalou N, et al. Protective effects of N-acetylcystein and atorvastatin against renal and hepatic injury in a rat model of intestinal ischemia-reperfusion.Biomed Pharmacother201789673–80

Atorvastatin; Mesenteric ischemia-reperfusion; N-acetylcysteine; Pretreatment; Rats

Copyright © 2019, the Chinese Medical Association.